Jaime Masferrer

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Rats
Mice

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Cortes-Burgos Luz A; Zweifel Ben S; Settle Steven L; Pufahl Robert A; Anderson Gary D; Hardy Medora M; Weir Dana E; Hu George; Happa Fernando A; Stewart Zachary; Muthian Shanmugam; Graneto Matthew J; Masferrer Jaime L
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Zweifel Ben S; Hardy Medora M; Anderson Gary D; Dufield Dawn R; Pufahl Robert A; Masferrer Jaime L
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Horrillo Raquel; Planagumà Anna; González-Périz Ana; Ferré Natàlia; Titos Esther; Miquel Rosa; López-Parra Marta; Masferrer Jaime L; Arroyo Vicente; Clària Joan
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jaime Masferrer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Cortes-Burgos Luz A; Zweifel Ben S; Settle Steven L; Pufahl Robert A; Anderson Gary D; Hardy Medora M; Weir Dana E; Hu George; Happa Fernando A; Stewart Zachary; Muthian Shanmugam; Graneto Matthew J; Masferrer Jaime L
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
European journal of pharmacology 2009;617(1-3):59-67.
2008: Zweifel Ben S; Hardy Medora M; Anderson Gary D; Dufield Dawn R; Pufahl Robert A; Masferrer Jaime L
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
European journal of pharmacology 2008;584(1):166-74.
2007: Horrillo Raquel; Planagumà Anna; González-Périz Ana; Ferré Natàlia; Titos Esther; Miquel Rosa; López-Parra Marta; Masferrer Jaime L; Arroyo Vicente; Clària Joan
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
The Journal of pharmacology and experimental therapeutics 2007;323(3):778-86.
2007: Pufahl Robert A; Kasten Thomas P; Hills Rob; Gierse James K; Reitz Beverly A; Weinberg Robin A; Masferrer Jaime L
Development of a fluorescence-based enzyme assay of human 5-lipoxygenase.
Analytical biochemistry 2007;364(2):204-12.
2005: Planagumà Anna; Clària Joan; Miquel Rosa; López-Parra Marta; Titos Esther; Masferrer Jaime L; Arroyo Vicente; Rodés Joan
The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(9):1120-2.
2005: Paccani Silvia Rossi; Patrussi Laura; Ulivieri Cristina; Masferrer Jaime L; D'Elios Mario Milco; Baldari Cosima T
Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling.
Blood 2005;105(5):2042-8.
2005: Gierse James K; Zhang Yan; Hood William F; Walker Mark C; Trigg Jennifer S; Maziasz Timothy J; Koboldt Carol M; Muhammad Jerry L; Zweifel Ben S; Masferrer Jaime L; Isakson Peter C; Seibert Karen
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1206-12.
2005: López-Parra Marta; Clària Joan; Titos Esther; Planagumà Anna; Párrizas Marcelina; Masferrer Jaime L; Jiménez Wladimiro; Arroyo Vicente; Rivera Francisca; Rodés Joan
The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.
Journal of hepatology 2005;42(1):75-81.
2004: Davis Thomas W; Zweifel Ben S; O'Neal Janet M; Heuvelman Deborah M; Abegg Ann L; Hendrich Todd O; Masferrer Jaime L
Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.
The Journal of pharmacology and experimental therapeutics 2004;308(3):929-34.
2004: Davis Thomas W; O'Neal Janet M; Pagel Mark D; Zweifel Ben S; Mehta Pramod P; Heuvelman Deborah M; Masferrer Jaime L
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Cancer research 2004;64(1):279-85.
2003: Lanza-Jacoby Susan; Miller Sheldon; Flynn John; Gallatig Kathleen; Daskalakis Constantine; Masferrer Jaime L; Zweifel Ben S; Sembhi Harjeet; Russo Irma H
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(12):1486-91.
2003: Davis Thomas W; Hunter Nancy; Trifan Ovidiu C; Milas Luka; Masferrer Jaime L
COX-2 inhibitors as radiosensitizing agents for cancer therapy.
American journal of clinical oncology 2003;26(4):S58-61.
2003: Masferrer Jaime L
Cyclooxygenase-2 inhibitors in cancer prevention and treatment.
Advances in experimental medicine and biology 2003;532():209-13.
2003: Blanke Charles D; Masferrer Jaime L
Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials.
Progress in experimental tumor research. Fortschritte der experimentellen Tumorforschung. Progrès de la recherche expérimentale des tumeurs 2003;37():243-60.
2003: López-Parra Marta; Clària Joan; Planagumà Anna; Titos Esther; Masferrer Jaime L; Woerner B Mark; Koki Alane T; Jiménez Wladimiro; Arroyo Vicente; Rivera Francisca; Rodés Joan
Renal effects of selective cyclooxygenase inhibition in experimental liver disease.
Advances in experimental medicine and biology 2003;525():133-6.
2002: Zweifel Ben S; Davis Thomas W; Ornberg Richard L; Masferrer Jaime L
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Cancer research 2002;62(22):6706-11.
2002: Trifan Ovidiu C; Durham William F; Salazar Valerie S; Horton Jennifer; Levine Benjamin D; Zweifel Ben S; Davis Thomas W; Masferrer Jaime L
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Cancer research 2002;62(20):5778-84.
2002: Howe Louise R; Subbaramaiah Kotha; Patel Jay; Masferrer Jaime L; Deora Aparna; Hudis Clifford; Thaler Howard T; Muller William J; Du Baoheng; Brown Anthony M C; Dannenberg Andrew J
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Cancer research 2002;62(19):5405-7.
2002: Koki Alane T; Masferrer Jaime L
Celecoxib: a specific COX-2 inhibitor with anticancer properties.
Cancer control : journal of the Moffitt Cancer Center 2002;9(2 Suppl):28-35.
2002: López-Parra Marta; Clària Joan; Planagumà Anna; Titos Esther; Masferrer Jaime L; Woerner B Mark; Koki Alane T; Jiménez Wladimiro; Altuna Rosario; Arroyo Vicente; Rivera Francisca; Rodés Joan
Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.
British journal of pharmacology 2002;135(4):891-900.
2002: Leahy Kathleen M; Ornberg Richard L; Wang Yu; Zweifel Ben S; Koki Alane T; Masferrer Jaime L
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Cancer research 2002;62(3):625-31.
2002: Koki A T; Khan N K; Woerner B M; Seibert K; Harmon J L; Dannenberg A J; Soslow R A; Masferrer J L
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.
Prostaglandins, leukotrienes, and essential fatty acids 2002;66(1):13-8.
2002: Koki Alane; Khan Nasir K; Woerner B Mark; Dannenberg A J; Olson Lisa; Seibert Karen; Edwards Dorothy; Hardy Madorra; Isakson Peter; Masferrer Jaime L
Cyclooxygenase-2 in human pathological disease.
Advances in experimental medicine and biology 2002;507():177-84.
2001: Khan K N; Masferrer J L; Woerner B M; Soslow R; Koki A T
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Scandinavian journal of gastroenterology 2001;36(8):865-9.
2001: Kulkarni S; Rader J S; Zhang F; Liapis H; Koki A T; Masferrer J L; Subbaramaiah K; Dannenberg A J
Cyclooxygenase-2 is overexpressed in human cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):429-34.
2000: Soslow R A; Dannenberg A J; Rush D; Woerner B M; Khan K N; Masferrer J; Koki A T
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
Cancer 2000;89(12):2637-45.
2000: Leahy K M; Koki A T; Masferrer J L
Role of cyclooxygenases in angiogenesis.
Current medicinal chemistry 2000;7(11):1163-70.
2000: Grubbs C J; Lubet R A; Koki A T; Leahy K M; Masferrer J L; Steele V E; Kelloff G J; Hill D L; Seibert K
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Cancer research 2000;60(20):5599-602.
2000: Khanna I K; Yu Y; Huff R M; Weier R M; Xu X; Koszyk F J; Collins P W; Cogburn J N; Isakson P C; Koboldt C M; Masferrer J L; Perkins W E; Seibert K; Veenhuizen A W; Yuan J; Yang D C; Zhang Y Y
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
Journal of medicinal chemistry 2000;43(16):3168-85.
2000: Masferrer J L; Leahy K M; Koki A T; Zweifel B S; Settle S L; Woerner B M; Edwards D A; Flickinger A G; Moore R J; Seibert K
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Cancer research 2000;60(5):1306-11.
2000: Talley J J; Brown D L; Carter J S; Graneto M J; Koboldt C M; Masferrer J L; Perkins W E; Rogers R S; Shaffer A F; Zhang Y Y; Zweifel B S; Seibert K
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.
Journal of medicinal chemistry 2000;43(5):775-7.
1999: Mohammed S I; Knapp D W; Bostwick D G; Foster R S; Khan K N; Masferrer J L; Woerner B M; Snyder P W; Koki A T
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.
Cancer research 1999;59(22):5647-50.
1999: Michaluart P; Masferrer J L; Carothers A M; Subbaramaiah K; Zweifel B S; Koboldt C; Mestre J R; Grunberger D; Sacks P G; Tanabe T; Dannenberg A J
Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation.
Cancer research 1999;59(10):2347-52.
1999: Talley J J; Bertenshaw S R; Brown D L; Carter J S; Graneto M J; Koboldt C M; Masferrer J L; Norman B H; Rogier D J; Zwwifel B S; Seibert K
4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2).
Medicinal research reviews 1999;19(3):199-208.
1999: Bosch-Marcè M; Clària J; Titos E; Masferrer J L; Altuna R; Poo J L; Jiménez W; Arroyo V; Rivera F; Rodés J
Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.
Gastroenterology 1999;116(5):1167-75.
1999: Carter J S; Kramer S; Talley J J; Penning T; Collins P; Graneto M J; Seibert K; Koboldt C M; Masferrer J; Zweifel B
Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.
Bioorganic & medicinal chemistry letters 1999;9(8):1171-4.
1999: Chan G; Boyle J O; Yang E K; Zhang F; Sacks P G; Shah J P; Edelstein D; Soslow R A; Koki A T; Woerner B M; Masferrer J L; Dannenberg A J
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.
Cancer research 1999;59(5):991-4.
1999: Tucker O N; Dannenberg A J; Yang E K; Zhang F; Teng L; Daly J M; Soslow R A; Masferrer J L; Woerner B M; Koki A T; Fahey T J
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Cancer research 1999;59(5):987-90.
1999: Masferrer J L; Koki A; Seibert K
COX-2 inhibitors. A new class of antiangiogenic agents.
Annals of the New York Academy of Sciences 1999;889():84-6.
1998: Smith C J; Zhang Y; Koboldt C M; Muhammad J; Zweifel B S; Shaffer A; Talley J J; Masferrer J L; Seibert K; Isakson P C
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(22):13313-8.
1997: Khanna I K; Weier R M; Yu Y; Xu X D; Koszyk F J; Collins P W; Koboldt C M; Veenhuizen A W; Perkins W E; Casler J J; Masferrer J L; Zhang Y Y; Gregory S A; Seibert K; Isakson P C
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.
Journal of medicinal chemistry 1997;40(11):1634-47.
1997: Seibert K; Zhang Y; Leahy K; Hauser S; Masferrer J; Isakson P
Distribution of COX-1 and COX-2 in normal and inflamed tissues.
Advances in experimental medicine and biology 1997;400A():167-70.
1996: Portanova J P; Zhang Y; Anderson G D; Hauser S D; Masferrer J L; Seibert K; Gregory S A; Isakson P C
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.
The Journal of experimental medicine 1996;184(3):883-91.
1996: Masferrer J L; Isakson P C; Seibert K
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.
Gastroenterology clinics of North America 1996;25(2):363-72.
1996: Li J J; Norton M B; Reinhard E J; Anderson G D; Gregory S A; Isakson P C; Koboldt C M; Masferrer J L; Perkins W E; Seibert K; Zhang Y; Zweifel B S; Reitz D B
Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
Journal of medicinal chemistry 1996;39(9):1846-56.
1996: Seibert K; Masferrer J L; Needleman P; Salvemini D
Pharmacological manipulation of cyclo-oxygenase-2 in the inflamed hydronephrotic kidney.
British journal of pharmacology 1996;117(6):1016-20.
1996: Salvemini D; Masferrer J L
Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies.
Methods in enzymology 1996;269():12-25.
1995: Salvemini D; Manning P T; Zweifel B S; Seibert K; Connor J; Currie M G; Needleman P; Masferrer J L
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors.
The Journal of clinical investigation 1995;96(1):301-8.
1995: Salvemini D; Settle S L; Masferrer J L; Seibert K; Currie M G; Needleman P
Regulation of prostaglandin production by nitric oxide; an in vivo analysis.
British journal of pharmacology 1995;114(6):1171-8.
1995: Seibert K; Masferrer J; Zhang Y; Leahy K; Hauser S; Gierse J; Koboldt C; Anderson G; Bremer M; Gregory S
Expression and selective inhibition of constitutive and inducible forms of cyclooxygenase.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():125-7.
1995: Isakson P; Seibert K; Masferrer J; Salvemini D; Lee L; Needleman P
Discovery of a better aspirin.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():49-54.
1995: Seibert K; Masferrer J; Zhang Y; Gregory S; Olson G; Hauser S; Leahy K; Perkins W; Isakson P
Mediation of inflammation by cyclooxygenase-2.
Agents and actions. Supplements 1995;46():41-50.
1995: Salvemini D; Seibert K; Masferrer J L; Settle S L; Misko T P; Currie M G; Needleman P
Nitric oxide and the cyclooxygenase pathway.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():491-3.
1994: Seibert K; Zhang Y; Leahy K; Hauser S; Masferrer J; Perkins W; Lee L; Isakson P
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12013-7.
1994: Isakson P; Hauser S; Zhang Y; Leahy K; Masferrer J; Seibert K
Cytokine regulation of eicosanoid generation.
Annals of the New York Academy of Sciences 1994;744():181-3.
1994: Masferrer J L; Reddy S T; Zweifel B S; Seibert K; Needleman P; Gilbert R S; Herschman H R
In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages.
The Journal of pharmacology and experimental therapeutics 1994;270(3):1340-4.
1994: Salvemini D; Seibert K; Masferrer J L; Misko T P; Currie M G; Needleman P
Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation.
The Journal of clinical investigation 1994;93(5):1940-7.
1994: Masferrer J L; Zweifel B S; Manning P T; Hauser S D; Leahy K M; Smith W G; Isakson P C; Seibert K
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(8):3228-32.
1994: Masferrer J L; Seibert K
Regulation of prostaglandin synthesis by glucocorticoids.
Receptor 1994;4(1):25-30.
1994: Seibert K; Masferrer J L
Role of inducible cyclooxygenase (COX-2) in inflammation.
Receptor 1994;4(1):17-23.
1993: Salvemini D; Misko T P; Masferrer J L; Seibert K; Currie M G; Needleman P
Nitric oxide activates cyclooxygenase enzymes.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(15):7240-4.
1992: Masferrer J L; Seibert K; Zweifel B; Needleman P
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(9):3917-21.
1991: Seibert K; Masferrer J L; FU J Y; Honda A; Raz A; Needleman P
The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity.
Advances in prostaglandin, thromboxane, and leukotriene research 1991;21A():45-51.
1990: Masferrer J L; Zweifel B S; Seibert K; Needleman P
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.
The Journal of clinical investigation 1990;86(4):1375-9.
1990: Fu J Y; Masferrer J L; Seibert K; Raz A; Needleman P
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.
The Journal of biological chemistry 1990;265(28):16737-40.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jaime Masferrer

Research Profile (preview)

Chemicals & Drugs

Living Beings

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jaime Masferrer (preview)

All Publications